James D. Peyton

464 total citations
27 papers, 363 citations indexed

About

James D. Peyton is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, James D. Peyton has authored 27 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in James D. Peyton's work include Lung Cancer Treatments and Mutations (11 papers), Cancer Treatment and Pharmacology (6 papers) and Gastric Cancer Management and Outcomes (5 papers). James D. Peyton is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer Treatment and Pharmacology (6 papers) and Gastric Cancer Management and Outcomes (5 papers). James D. Peyton collaborates with scholars based in United States, Canada and United Kingdom. James D. Peyton's co-authors include John D. Hainsworth, David R. Spigel, Howard A. Burris, Anthony A. Meluch, Cassie M. Lane, Dianna Shipley, Mark A. Rubin, Johanna C. Bendell, David Waterhouse and F. Anthony Greco and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

James D. Peyton

27 papers receiving 356 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James D. Peyton United States 10 200 175 145 61 53 27 363
Satomi Yamamoto Japan 8 193 1.0× 118 0.7× 173 1.2× 37 0.6× 61 1.2× 22 366
Daniel P. Petro United States 11 243 1.2× 188 1.1× 194 1.3× 39 0.6× 49 0.9× 21 428
Patrick Chun United States 9 243 1.2× 142 0.8× 101 0.7× 28 0.5× 36 0.7× 19 364
Eric Xueyu Chen Canada 9 187 0.9× 126 0.7× 85 0.6× 66 1.1× 93 1.8× 54 370
Jiahuai Wen China 10 161 0.8× 162 0.9× 67 0.5× 58 1.0× 164 3.1× 17 380
Özge Gümüşay Türkiye 11 164 0.8× 100 0.6× 124 0.9× 30 0.5× 78 1.5× 42 350
Varalakshmi Janamanchi United States 3 160 0.8× 273 1.6× 195 1.3× 36 0.6× 62 1.2× 5 498
Xiaonan Shi China 12 103 0.5× 161 0.9× 76 0.5× 39 0.6× 111 2.1× 22 333
Wen-Son Hsieh United States 6 177 0.9× 135 0.8× 138 1.0× 19 0.3× 62 1.2× 9 329
Mark D. Kochenderfer United States 9 231 1.2× 142 0.8× 201 1.4× 62 1.0× 75 1.4× 14 366

Countries citing papers authored by James D. Peyton

Since Specialization
Citations

This map shows the geographic impact of James D. Peyton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James D. Peyton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James D. Peyton more than expected).

Fields of papers citing papers by James D. Peyton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James D. Peyton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James D. Peyton. The network helps show where James D. Peyton may publish in the future.

Co-authorship network of co-authors of James D. Peyton

This figure shows the co-authorship network connecting the top 25 collaborators of James D. Peyton. A scholar is included among the top collaborators of James D. Peyton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James D. Peyton. James D. Peyton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bendell, Johanna C., Joleen M. Hubbard, Bert H. O’Neil, et al.. (2017). Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/− bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts). Annals of Oncology. 28. iii150–iii151. 7 indexed citations
3.
Ko, Andrew H., Patrick Murphy, James D. Peyton, et al.. (2017). A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. The Oncologist. 22(12). 1427–e129. 38 indexed citations
4.
Bendell, Johanna C., Joleen M. Hubbard, Bert H. O’Neil, et al.. (2017). Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology. 35(15_suppl). 3529–3529. 12 indexed citations
5.
6.
7.
Bendell, Johanna C., Ahmed Zakari, James D. Peyton, et al.. (2016). A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only. The Oncologist. 21(3). 279–280d. 14 indexed citations
8.
9.
Waterhouse, David, John D. Hainsworth, Frank A. Greco, et al.. (2012). Adjuvant carboplatin, docetaxel, bevacizumab, and erlotinib versus chemotherapy alone in patients with resected non-small cell lung cancer: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).. Journal of Clinical Oncology. 30(15_suppl). 7035–7035. 2 indexed citations
10.
Bendell, Johanna C., Anthony A. Meluch, James D. Peyton, et al.. (2012). A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer.. PubMed. 10(7). 430–7. 42 indexed citations
11.
Hainsworth, John D., David R. Spigel, F. Anthony Greco, et al.. (2011). Combined Modality Treatment With Chemotherapy, Radiation Therapy, Bevacizumab, and Erlotinib in Patients With Locally Advanced Squamous Carcinoma of the Head and Neck. The Cancer Journal. 17(5). 267–272. 49 indexed citations
12.
Spigel, David R., John D. Hainsworth, Dianna Shipley, et al.. (2011). A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 7(1). 196–202. 25 indexed citations
13.
Peyton, James D., Jordi Rodón, Carolyn D. Britten, et al.. (2011). A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3066–3066. 39 indexed citations
14.
Spigel, David R., John D. Hainsworth, Victor G. Gian, et al.. (2010). A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer. Journal of Thoracic Oncology. 5(6). 862–866. 4 indexed citations
15.
Hainsworth, John D., Jeffrey R. Infante, David R. Spigel, et al.. (2010). Bevacizumab and everolimus in the treatment of patients with metastatic melanoma. Cancer. 116(17). 4122–4129. 62 indexed citations
16.
Yardley, Denise A., Davey B. Daniel, Mark Mainwaring, et al.. (2010). A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer. Cancer Investigation. 28(8). 865–871. 4 indexed citations
17.
Spigel, David R., F. Anthony Greco, Thomas J. Ervin, et al.. (2010). A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.. Journal of Clinical Oncology. 28(15_suppl). 7593–7593. 1 indexed citations
18.
Meluch, Anthony A., H.A. Burris, Cassie M. Lane, et al.. (2009). Combined modality therapy with radiation therapy (RT), chemotherapy, bevacizumab, and erlotinib in the treatment of patients (pts) with locally advanced squamous carcinoma of the head and neck. Journal of Clinical Oncology. 27(15_suppl). 6012–6012. 9 indexed citations
19.
Peyton, James D., David R. Spigel, Howard A. Burris, et al.. (2009). Phase II trial of bevacizumab and everolimus in the treatment of patients with metastatic melanoma: Preliminary results. Journal of Clinical Oncology. 27(15_suppl). 9027–9027. 9 indexed citations
20.
Meluch, Anthony A., David R. Spigel, F. Anthony Greco, et al.. (2007). Phase I/II trial of preoperative oxaliplatin, docetaxel, capecitabine, and radiation for localized esophageal cancer. Journal of Clinical Oncology. 25(18_suppl). 4595–4595. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Satomi Yamamoto Breakdown of academic impact, for papers by Daniel P. Petro Breakdown of academic impact, for papers by Patrick Chun Breakdown of academic impact, for papers by Eric Xueyu Chen Breakdown of academic impact, for papers by Jiahuai Wen Breakdown of academic impact, for papers by Özge Gümüşay Breakdown of academic impact, for papers by Varalakshmi Janamanchi Breakdown of academic impact, for papers by Xiaonan Shi Breakdown of academic impact, for papers by Wen-Son Hsieh Breakdown of academic impact, for papers by Mark D. Kochenderfer
Rankless by CCL
2026